市场见解

The Imugene (ASX:IMU) share price has rocketed 80% since August. Here’s why

Shares in the biopharma company are enjoying a good run this year. We take a closer look
The post The Imugene (ASX:IMU) share price has rocketed 80% since August. Here’s why appeared first on The Motley Fool Australia. –

The Imugene Limited (ASX: IMU) share price is flat at 52.5 cents in early trade today after finishing 4.5% in the red yesterday.

However, shares in the biopharma company have climbed 17% in the past month. They are also up 81% since the start of August, adding to their impressive run in the last year.

A string of fundamental updates from the company has investors placing bids to secure a spot in Imugene. Let’s take a closer look at what’s been driving returns lately.

What’s up with Imugene lately?

The Imugene share price started rising again in mid-October, bouncing off a low of 39.5 cents. Back then the company released an investor presentation on its technology and treatment platforms.

Even with the company’s operations and clinical trial milestones on full display, investors had a dull reaction to the update.

Although, investors have been rewarding ASX health care shares these past few months, indicating strengths in the broad sector. For instance, around the same time in October, the S&P/ASX 200 Health Care index (ASX: XHJ) also sprung off its low and accelerated north.

Imugene then announced its strategic partnership with clinical-stage biotechnology company Eureka Therapeutics on November 1. The pair are set to explore the therapeutic potential of combining technologies for the treatment of solid tumours. The Imugene share price jumped on the news.

Following this, Imugene advised of a new clinical supply agreement with pharmaceutical giants Merck KGaA (ETR: MRK) and Pfizer Inc (NYSE: PFE).

Merck has been on the quest to develop novel treatment solutions in oncology over the past few years, so too has Pfizer. As such, the trio will investigate Imugene’s HER-Vaxx therapy in combination with Avelumab, co-developed by Pfizer and Merck.

Whereas HER-Vaxx is specifically designed to treat tumours, Avelumab works by blocking a certain molecule that suppresses the immune system.

The Phase 2 trial will investigate how effective HER-Vaxx and Avelumab are as a combination therapy with chemotherapy versus placebo with a certain type of gastric/gastroesophageal cancer.

Imugene share price snapshot

After closing as high as 60.5 cents on 9 November, the Imugene share price has cooled off and marched back to its current levels.

Imugene shares have soared more than 377% in the past 12 months and 425% this year to date.

Despite this, they have levelled off in the past 2 weeks and are down around 3% in the past week. It hasn’t been all downhill in this time, however, with the share still closing on top on a number of trading days.

For context, the S&P/ASX 200 index (ASX: XJO) has gained around 10% over the past 12 months and 12% this year to date.

The post The Imugene (ASX:IMU) share price has rocketed 80% since August. Here’s why appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene right now?

Before you consider Imugene, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Here are the top 10 ASX shares today

Why Calix, Imugene, Legacy Iron Ore, and Lovisa shares are charging higher

Imugene (ASX:IMU) share price leaps 9% on Pfizer, Merck deal

Here are the top 10 ASX shares today

Here are the top 10 ASX shares today

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!